Kelzy

Dienogest/Ethinylestradiol, the active ingredient in Kelzy, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by regulating hormonal cycles. The formulation contains a synthetic progestogen (dienogest) and an estrogen (ethinylestradiol) that work together to inhibit ovulation and create an unfavorable environment for fertilisation. GNH USA supplies Kelzy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with consistent quality and regulatory compliance.

Kelzy, a combined oral contraceptive, is indicated for several reproductive‑health applications. - Contraception: Prevents pregnancy by inhibiting ovulation and altering cervical mucus. - Menstrual cycle regulation: Provides predictable withdrawal bleeding and reduces cycle irregularities. - Moderate acne treatment: Improves acne lesions through hormonal regulation in women.

Kelzy may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hypertensive crisis: sudden high‑blood‑pressure episodes. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Kelzy, clinicians should evaluate the following safety considerations. - Contraindication: Do not use in women with known or suspected pregnancy. - Cardiovascular risk: Avoid in patients with history of thromboembolic disorders, stroke, or uncontrolled hypertension. - Smoking: Caution in women over 35 who smoke, as risk of cardiovascular events increases. - Liver disease: Use with caution in patients with active liver disease or impaired hepatic function. - Drug interactions: Review concomitant medications that may affect estrogen metabolism. - Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture and light.

Kelzy can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Combined hormonal contraceptives with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce contraceptive efficacy. - Anticoagulants (warfarin) may have altered plasma levels when used with estrogen‑containing pills. - Certain antiretrovirals (e.g., efavirenz) can significantly decrease hormone concentrations.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole) may increase estrogen levels, raising risk of side effects. - Selective serotonin reuptake inhibitors (SSRIs) may modestly affect platelet function. - Herbal supplements containing St. John’s wort can lower hormone levels.